PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology

PURPOSE OF REVIEW: PCSK9 inhibitors have been shown to be the most effective class of drugs modifying the levels of LDL-cholesterol as the main risk factor for atherosclerotic cardiovascular disease. The aim of this paper is to assess the effect of monoclonal antibodies on lipid and lipoprotein meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Altschmiedová, Tereza, Todorovová, Veronika, Šnejdrlová, Michaela, Šatný, Martin, Češka, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Statin Drugs (R. Ceska, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810794/
https://www.ncbi.nlm.nih.gov/pubmed/35332442
http://dx.doi.org/10.1007/s11883-022-01008-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810794/
https://www.ncbi.nlm.nih.gov/pubmed/35332442
http://dx.doi.org/10.1007/s11883-022-01008-8

Ejemplares similares